x

Posted 27 February, 2023

BioAtla, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:BCAB in a 8-K filed on 27 February, 2023.


  On February 24, 2023, Scott Smith, President of BioAtla, Inc. ("BioAtla") notified BioAtla of his intention to resign, effective February 27, 2023, in order to pursue a new opportunity as Chief Executive Officer at Viatris Inc.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of BioAtla, Inc.
Health Care/Life Sciences • Biotechnology
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Market Cap
$132M
View Company Details
BioAtla, Inc. by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On February 24, 2023, Scott Smith, President of BioAtla, Inc. ("BioAtla") notified BioAtla of his intention to resign, effective February 27, 2023, in order to pursue a new opportunity as Chief Executive Officer at Viatris Inc. Mr. Smith will continue to serve as a director on the board of directors (the "Board") of BioAtla, and his equity awards will continue to vest based on his continued service on the Board. 

A copy of the press release issued by the Company announcing the resignation of Mr. Smith is attached to this report as Exhibit 99.1 and incorporated herein by reference.